Study Summary
This study is evaluating whether a combination of immunotherapy and chemotherapy may help treat gastroesophageal cancer.
- Unresectable Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage III Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma
- Stage IV Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (pembrolizumab, chemoradiotherapy)
1 of 1
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What medical conditions has Pembrolizumab been approved to treat?
"Pembrolizumab has been found to be effective in treating malignant neoplasms and other health issues such as unresectable melanoma, rectal carcinoma, and microsatellite instability high." - Anonymous Online Contributor
Has the FDA granted its official authorization for Pembrolizumab?
"Limited data on pembrolizumab's safety and efficacy has caused our team to assign it a rating of 1." - Anonymous Online Contributor
What is the total sample size of this research experiment?
"Affirmative. Clinicaltrials.gov indicates that the trial, which was first published on September 16th 2020, is currently seeking participants. 15 individuals must be recruited from a single clinical site." - Anonymous Online Contributor
Are there any vacancies in this trial for participants?
"Via clinicaltrials.gov, we know that this medical study is actively seeking participants. The trial was originally published on September 16th 2020 and recently edited as of October 10th 2022." - Anonymous Online Contributor
Are there any existing reports of Pembrolizumab being tested in other research projects?
"As of the present day, 1653 separate experiments are exploring Pembrolizumab's capabilities with 375 trials within Phase 3. Guangzhou, Guangdong is a particularly active location in regard to these studies; however, there exists 71618 other sites engaging in research involving Pembrolizumab." - Anonymous Online Contributor